EMG
NTLA icon

Ellington Management Group’s Intellia Therapeutics NTLA Stock Holding History

Ellington Management Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-19,200
Closed -$307K – 786
2017
Q2 		$307K Buy
+19,200
New +$268K 0.04% 387

Other funds holding NTLA

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
GTP
Global Thematic Partners New York $120M AUM 25.18% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Ellington Management Group's NTLA Position: Q3 2017 in Review

Ellington Management Group sold out of Intellia Therapeutics (NTLA) in Q3 2017, closing a stake of 19,200 shares — an estimated $307K sold.

Ellington Management Group first reported a position in NTLA in Q2 2017 and held it in 1 quarter. The position peaked at $307K in Q2 2017. 85 funds tracked by Wall St. Rank hold NTLA as of Q3 2017.

  • Ellington Management Group reported no remaining Intellia Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Ellington Management Group sold 19,200 Intellia Therapeutics shares in Q3 2017, an estimated $307K.
  • Ellington Management Group first reported a position in Intellia Therapeutics in Q2 2017 and held it in 1 quarter.
  • Ellington Management Group's Intellia Therapeutics position peaked at $307K in Q2 2017.
  • 85 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2017.

Based on Ellington Management Group's 13F filing for Q3 2017, filed 14 Nov 2017.